Mutares: The Market Is Still Counting the Capital Raise, While the Adjusted EBITDA Already Flipped

The share price is down roughly 19.93% over the past year. The covenant breach in March, the capital raise in April, the auditor scrutiny in the summer of 2025 - the headlines have done their job. Investors anchored to a private equity holding company that borrowed too much, bought too fast, and then had to raise equity on dilution terms. The market is still pricing that story.

Then Mutares publishes its first-half 2026 results today, August 4. Group revenues of EUR 3.4 billion, up 9 percent year-over-year. Adjusted EBITDA - the measure that strips out the noise from bargain-purchase gains and exits, leaving the operating cash generation - is EUR 67 million. Six months ago it was minus EUR 89 million. The flip is the whole point.

The old story: overextension.

Mutares is a Munich-based listed private equity firm. It buys companies in distress or transition, restructures them, and sells them at a profit. The holding company itself earns management fees and consulting income from portfolio companies, while the real money comes from exit gains - selling a portfolio company for more than it cost.

The model is aggressive by design. In fiscal 2025, group revenues hit EUR 6.5 billion (up from EUR 5.3 billion the year before) and the holding's net income reached EUR 130.4 million. But the acquisition machine pushed consolidated net debt/equity above the 1.5/1 covenant on both outstanding bonds. The breach triggered a consent vote with bondholders in March 2026, a capital increase raising approximately EUR 105 million at EUR 24.50 per share in April, and a wave of negative press. The share price tracked all of it downward.

That capital raise and covenant drama are what the tape still remembers. They're also what the numbers have already moved past.

The proof path: adjusted EBITDA turned positive.

H1 2026 adjusted EBITDA at EUR 67 million versus minus EUR 89 million in H1 2025. That is not a margin exercise - it is an operational one. Nine portfolio companies - Efacec, SFC Solutions, Guascor Energy, NEM Energy Group, Alterga, Gemini Rail, HILO Group, Donges, and Kuljettava - are now producing clearly positive adjusted EBITDA after restructuring. Donges alone has grown from EUR 35 million in sales to more than EUR 110 million with profitability approaching 10 percent.

The holding company's adjusted net result for H1 2026 sits at EUR 6 million. That looks small compared to EUR 70 million a year ago, but the comparison is distorted: the full exit of Steyr Motors in 2025 contributed the bulk of last year's H1 number. There were no exits in Q1 2026, and the company also booked a EUR 6 million consent fee related to the bond process. Strip those items out and the consulting business - the recurring fee income - is generating positive earnings, as management has said all along.

What matters going forward is the exit pipeline. Mutares says it has the largest exit pipeline in its history, with several sale processes at various stages of maturity. Magirus has already seen order intake reach record levels in Q1 2026 with a backlog exceeding EUR 800 million, and Mutares initiated exit preparation in May. The company says significant exit proceeds are expected in H2 from already-signed agreements.

What the market is misreading.

The capital raise was necessary but not damning. The EUR 105 million injection was used approximately 80 percent for further expansion in the U.S. - where Mutares is evaluating roughly 15 targets across energy, chemicals, manufacturing, infrastructure, and automotive - and 20 percent to strengthen the balance sheet. Bond covenants are now fully complied with as of June 30, 2026.

The SABIC acquisition - Engineering Thermoplastics, now renamed NexPoint Materials - is the largest transaction in the company's history. EUR 2 billion in annual revenues, eight production sites across the Americas and Europe, roughly 2,800 employees. It closed in early August 2026. The business will flow through H2 2026 results and beyond, though management has acknowledged it needs restructuring after years of pressure from a weak chemical cycle.

The guidance tells the whole story. Management projects EUR 7.9 billion to EUR 9.1 billion in group revenues for full-year 2026, up from EUR 6.5 billion in 2025. Holding net income guidance sits at EUR 165 million to EUR 200 million, versus EUR 130.4 million in 2025. The range is backed by the sell-side exit pipeline and the buy-side revenue expansion. If H1 adjusted EBITDA already flipped to EUR 67 million with no exits in Q1, the second half - with exits expected and the SABIC revenue contribution arriving - should show the trajectory more clearly.

Medium-term targets through 2030 call for 25% annual growth in both group revenues and holding net income. That is aggressive, but the company has hit its numbers before.

The financial bridge.

Holding net income of EUR 165 million to EUR 200 million for 2026. The company proposed a EUR 2 dividend per share for the 2026 annual general meeting, which works out to roughly a 7.39% yield at current prices.

The upside from here is not a function of sentiment reversal. It is a function of exit proceeds showing up in the next two reporting windows and the multiple adjusting from "covenant-breach risk" to "recurring fee plus exit engine."

What could break it.

The adjusted EBITDA number still carries headwinds. Retail operations in the Goods & Services segment - Lapeyre, Prénatal, Stuart, La Rochette, Natura - remain negative contributors. The SABIC/NexPoint Materials business needs restructuring work. And a large part of 2026 guidance depends on exits actually closing, which is never guaranteed.

The new US expansion plan is exciting but expensive. The 80 percent allocation of the capital raise to US acquisitions means more leverage and more integration risk. If those deals underperform or the exit pipeline stalls, the balance sheet will face pressure again.

The setup is this: the market has already priced the worst of the capital-raise and covenant drama. The adjusted EBITDA flip in H1 shows the operating engine is improving underneath. The second half should bring exit proceeds and SABIC revenue that make the trajectory harder to dismiss. If holding net income reaches anywhere near the guidance midpoint, the current share price starts looking like a discount to a working model rather than a cautionary tale.

The tripwire is the exit pipeline. If H2 2026 exits fail to materialize or adjusted EBITDA falls back below zero, the rerating case evaporates. If they close as expected, the numbers do the talking.